S

Stryker

Manufactures orthopedic and surgical medical devices

Enabling Technologies Capital Sales Account Executive

Full-Time
No salary listed
Senior
Bachelor's
London, UK+2 moreMore locations: South London, UK | East London, UK
In PersonResidency is limited to London, South East UK, the M4 Corridor, the Midlands, or South Central UK. Extensive travel of 80% or more is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A Bachelor's degree (BA/BSc) with at least five years of proven success in spine surgical or medical capital equipment sales is required.
  • Strong experience managing complex capital sales cycles, including on-budget and off-budget processes, is required.
  • Demonstrated ability to engage credibly with surgeons, allied healthcare professionals, and executive hospital leadership, including CEOs, CFOs, and COOs, is required.
  • Proven capability to translate clinical benefits into economic value, with a solid understanding of hospital financial operations and procurement processes, is required.
  • Experience influencing and managing C-suite stakeholders through executive-level selling is required.
  • Excellent presentation, communication, and negotiation skills, both verbal and written, are required.
  • Strong strategic thinking, process orientation, and the ability to manage a large geographic territory are required.
  • Willingness to travel extensively, at least 80%, is required.
  • A valid driver's license is required.
  • Fluency in English at a native or near-native level is required.
Responsibilities
  • Drive sales of high-value capital equipment within the Enabling Technologies portfolio.
  • Develop and maintain strong relationships with existing and prospective customers.
  • Identify, qualify, and manage new business opportunities and sales leads.
  • Lead complex capital sales cycles, including on-budget and off-budget processes.
  • Build and present business cases, return-on-investment analyses, and financial proposals to senior hospital stakeholders, including Procurement, CFO, and C-suite stakeholders.
  • Negotiate sales agreements and service contracts.
  • Lead cross-functional teams supporting sales, installation, and post-sale training.
  • Partner with Marketing, Sales Management, and Finance to execute territory and account strategies.
  • Provide accurate forecasting and timely reporting of account activities.
  • Represent the company at sales meetings, training events, and industry conferences.
Desired Qualifications
  • Demonstrated experience selling large capital equipment, with typical contract values ranging from £250,000 to £1.5 million.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stryker Corporation
Oct 27th, 2026
Stryker Completes Acquisition of MAKO Surgical Corp.

Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics. "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals," said Kevin A. Lobo, President and Chief Executive Officer. As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in

Yahoo Finance
Oct 21st, 2026
P&G and Stryker: two dividend stocks to hold for decades

Procter & Gamble and Stryker are two dividend stocks suited to long-term holders, according to the article. Both sell products people need in any economy. P&G has raised its dividend for 70 consecutive years. In fiscal 2026, it posted net sales of about $87 billion, up 3%, and net earnings of $16.1 billion. It returned more than $15 billion to shareholders, including $10.2 billion in dividends. Organic sales and core earnings per share each grew just 1%. Stryker has raised its dividend for more than three decades. Second-quarter 2026 revenue rose 9.4% to $6.6 billion, and adjusted earnings per share climbed 17.9% to $3.69. Demand should gain from an ageing US population, though recalls, acquisition costs, and hospital spending pressures remain risks.

Yahoo Finance
Oct 14th, 2026
Stryker wins FDA clearance for Sonopet 3 ultrasonic bone and tissue removal platform

Stryker has received US Food and Drug Administration (FDA) 510(k) clearance for Sonopet 3, the latest version of its ultrasonic bone and soft tissue removal platform. The company announced the news on October 14, 2026. Stryker developed the platform with input from hundreds of surgeons. It offers more power, precision and versatility, along with two technologies: RISE, which connects the surgical workflow, and Pulse Control, which helps regulate the resection of hard and soft tissues. "They told us they wanted more power, improved ergonomics and enhanced integration," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. The first clinical cases are expected to begin in October. A full commercial launch is planned for later this fall.

Yahoo Finance
Oct 12th, 2026
Stryker shares fall 20% in six months despite 9.2% organic growth and $25.84B revenue

Stryker (NYSE:SYK) shares have fallen 20% over the past six months to $277.82, while the S&P 500 gained 12.8%. The medical device maker develops orthopedic, surgical, neurotechnology, and patient care products that reach over 150 million patients a year. Organic revenue, which excludes acquisitions, divestitures, and currency swings, grew an average of 9.2% year-on-year over the past two years. That suggests Stryker can expand without costly acquisitions. Revenue over the past 12 months was $25.84 billion. Its scale gives it leverage with suppliers in a heavily regulated, competitive market. Free cash flow margin rose 6.5 percentage points over five years to 18.2% for the trailing 12 months. After the drop, the stock trades at 17.4× forward earnings.

Seeking Alpha
Oct 12th, 2026
Stryker to invest $400M in CMR Surgical, with option to buy the robotics maker outright

Stryker announced a $400 million (£300 million) preferred equity investment in CMR Surgical on Monday. The money will support innovation and global expansion of CMR's Versius surgical robotics portfolio. The deal also gives Stryker an exclusive option to acquire 100% of CMR Surgical.